Related references
Note: Only part of the references are listed.Genomic Profiling of Metastatic Uveal Melanoma Shows Frequent Coexisting BAP1 or SF3B1 and GNAQ/GNA11 Mutations and Correlation With Prognosis
Alexandra L. Isaacson et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2022)
In uveal melanoma Gα-protein GNA11 mutations convey a shorter disease-specific survival and are more strongly associated with loss of BAP1 and chromosomal alterations than Gα-protein GNAQ mutations
Francesca Piaggio et al.
EUROPEAN JOURNAL OF CANCER (2022)
Role of somatic mutations and chromosomal aberrations in the prognosis of uveal melanoma in a Spanish patient cohort
Paula Silva-Rodriguez et al.
ACTA OPHTHALMOLOGICA (2021)
Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
Tyler D. Hitchman et al.
CLINICAL CANCER RESEARCH (2021)
MEK-ing the Most of It: Strategies to Co-target Gαq and MAPK in Uveal Melanoma
Sathya Neelature Sriramareddy et al.
CLINICAL CANCER RESEARCH (2021)
Functional characterization of uveal melanoma oncogenes
Jiafang Ma et al.
ONCOGENE (2021)
Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma
Justine S. Paradis et al.
CLINICAL CANCER RESEARCH (2021)
Current molecular and clinical insights into uveal melanoma (Review)
Matteo Fallico et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2021)
Development of new therapeutic options for the treatment of uveal melanoma
Janney Z. Wang et al.
FEBS JOURNAL (2021)
Genetic Landscape and Emerging Therapies in Uveal Melanoma
Rino S. Seedor et al.
CANCERS (2021)
Prognostic Values of G-Protein Mutations in Metastatic Uveal Melanoma
Mizue Terai et al.
CANCERS (2021)
Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma
Svenja Mergener et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Targeting primary and metastatic uveal melanoma with a G protein inhibitor
Michael D. Onken et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)
Jason J. Luke et al.
CLINICAL CANCER RESEARCH (2020)
Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy.
Shaheer Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Uveal melanoma
Martine J. Jager et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Targeted Next-Generation Sequencing of 117 Routine Clinical Samples Provides Further Insights into the Molecular Landscape of Uveal Melanoma
Sophie Thornton et al.
CANCERS (2020)
Update on GNA Alterations in Cancer: Implications for Uveal Melanoma Treatment
Lionel Larribere et al.
CANCERS (2020)
Treatment of Metastatic Uveal Melanoma: Systematic Review
Cristina Rodriguez-Vidal et al.
CANCERS (2020)
Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma
Fabiana Mallone et al.
CANCERS (2020)
Prognostic Factors Five Years After Enucleation for Uveal Melanoma
Mehmet Dogrusoz et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2020)
Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas
Bjoern Schneider et al.
PATHOLOGY & ONCOLOGY RESEARCH (2019)
A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK
Xiaodong Feng et al.
CANCER CELL (2019)
Structure-Activity Relationship Studies of the Natural Product Gq/11 Protein Inhibitor YM-254890
Xiao-Feng Xiong et al.
CHEMMEDCHEM (2019)
Next-Generation Sequencing of Uveal Melanoma for Detection of Genetic Alterations Predicting Metastasis
Armin R. Afshar et al.
TRANSLATIONAL VISION SCIENCE & TECHNOLOGY (2019)
Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives
Michela Croce et al.
CANCERS (2019)
Do GNAQ and GNA11 Differentially Affect Inflammation and HLA Expression in Uveal Melanoma?
Christiaan van Weeghel et al.
CANCERS (2019)
Secondary Somatic Mutations in G-Protein-Related Pathways and Mutation Signatures in Uveal Melanoma
Francesca Piaggio et al.
CANCERS (2019)
Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma
Dominic Lapadula et al.
MOLECULAR CANCER RESEARCH (2019)
YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression
Huapeng Li et al.
CELL REPORTS (2019)
Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations
Getachew Boru et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2019)
A Phase I trial of LXS196, a novel PKC inhibitor for metastatic uveal melanoma
Ellen Kapiteijn et al.
CANCER RESEARCH (2019)
The Role of Mutation Rates of GNAQ or GNA11 in Cases of Uveal Melanoma in Japan
Jun Ominato et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2018)
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma (vol 32, pg 204, 2017)
A. Gordon Robertson et al.
CANCER CELL (2018)
Genetic and epigenetic insights into uveal melanoma
A. Sharma et al.
CLINICAL GENETICS (2018)
Structure-activity relationship and conformational studies of the natural product cyclic depsipeptides YM-254890 and FR900359
Hang Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
An insight into the molecular genetics of a uveal melanoma patient cohort
Susan Kennedy et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
Richard D. Carvajal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combined mutation and copy-number variation detection by targeted next-generation sequencing in uveal melanoma
Kyra N. Smit et al.
MODERN PATHOLOGY (2018)
Selumetinib-based therapy in uveal melanoma patient-derived xenografts
Didier Decaudin et al.
Oncotarget (2018)
GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma
Amanda R. Moore et al.
CELL REPORTS (2018)
Targeting nucleotide exchange to inhibit constitutively active G protein a subunits in cancer cells
Michael D. Onken et al.
SCIENCE SIGNALING (2018)
Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma
Kjersti M. Staby et al.
ACTA OPHTHALMOLOGICA (2018)
Regulation of localization and function of the transcriptional co-activator YAP by angiomotin
Susana Moleirinho et al.
ELIFE (2017)
Uveal Melanoma: GNAQ and GNA11 Mutations in a Greek Population
Filippos Psinakis et al.
ANTICANCER RESEARCH (2017)
GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi
M. J. C. Vader et al.
BRITISH JOURNAL OF CANCER (2017)
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma
A. Gordon Robertson et al.
CANCER CELL (2017)
RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma
Xu Chen et al.
CANCER CELL (2017)
Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4
Peter Johansson et al.
ONCOTARGET (2016)
Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing
Beryl Royer-Bertrand et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2016)
ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma
Jae Hyuk Yoo et al.
CANCER CELL (2016)
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma
Alexander N. Shoushtari et al.
MELANOMA RESEARCH (2016)
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma
Amanda R. Moore et al.
NATURE GENETICS (2016)
Uveal Melanomas with SF3B1 Mutations A Distinct Subclass Associated with Late-Onset Metastases
Serdar Yavuzyigitoglu et al.
OPHTHALMOLOGY (2016)
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma
Guillaume Carita et al.
ONCOTARGET (2016)
Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish
Mai Abdel Mouti et al.
ONCOTARGET (2016)
Driver Mutations in Uveal Melanoma Associations With Gene Expression Profile and Patient Outcomes
Christina L. Decatur et al.
JAMA OPHTHALMOLOGY (2016)
Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)
Richard D. Carvajal et al.
BMC CANCER (2015)
The experimental power of FR900359 to study Gq-regulated biological processes
Ramona Schrage et al.
NATURE COMMUNICATIONS (2015)
Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma
M. Dono et al.
BRITISH JOURNAL OF CANCER (2014)
Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP
Fa-Xing Yu et al.
CANCER CELL (2014)
Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry
Xiaodong Feng et al.
CANCER CELL (2014)
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma A Randomized Clinical Trial
Richard D. Carvajal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Genetic and clinico-pathologic analysis of metastatic uveal melanoma
Klaus G. Griewank et al.
MODERN PATHOLOGY (2014)
The Phosphoinositide 3-Kinase α Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells
Elgilda Musi et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target
Nabil Amirouchene-Angelozzi et al.
MOLECULAR ONCOLOGY (2014)
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations
X. Chen et al.
ONCOGENE (2014)
Combined PKC and MEK inhibition for treating metastatic uveal melanoma
M. S. Sagoo et al.
ONCOGENE (2014)
Oncogenic GNAQ and GNA11 Mutations in Uveal Melanoma in Chinese
Xiaolin Xu et al.
PLOS ONE (2014)
Chromosome 3 Status Combined With BAP1 and EIF1AX Mutation Profiles Are Associated With Metastasis in Uveal Melanoma
Kathryn G. Ewens et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2014)
FAK in cancer: mechanistic findings and clinical applications
Florian J. Sulzmaier et al.
NATURE REVIEWS CANCER (2014)
Protein Kinase C Inhibitors Sensitize GNAQ Mutant Uveal Melanoma Cells to Ionizing Radiation
Jasmina Ziva Cerne et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2014)
Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma.
Sophie Piperno-Neumann et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11
A. E. Koopmans et al.
BRITISH JOURNAL OF CANCER (2013)
Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
Oliver Surriga et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3
Marcel Martin et al.
NATURE GENETICS (2013)
Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma
J. William Harbour et al.
NATURE GENETICS (2013)
SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma
Simon J. Furney et al.
CANCER DISCOVERY (2013)
A Landscape of Driver Mutations in Melanoma
Eran Hodis et al.
CELL (2012)
Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
John M. Kirkwood et al.
CLINICAL CANCER RESEARCH (2012)
Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner
Jahan S. Khalili et al.
CLINICAL CANCER RESEARCH (2012)
Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance
Grazia Ambrosini et al.
CLINICAL CANCER RESEARCH (2012)
Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-κB Pathways
Xinqi Wu et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET ONCOLOGY (2012)
The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma
Xinqi Wu et al.
PLOS ONE (2012)
Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype
Alan L. Ho et al.
PLOS ONE (2012)
High Throughput Mass Spectrometry-Based Mutation Profiling of Primary Uveal Melanoma
Anthony B. Daniels et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2012)
Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas
Helena Populo et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2011)
Uveal Melanoma: Trends in Incidence, Treatment, and Survival
Arun D. Singh et al.
OPHTHALMOLOGY (2011)
Uveal Melanoma and GNA11 Mutations: a new piece added to the puzzle
Ahmad Besaratinia et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
Mutations in GNA11 in Uveal Melanoma.
Catherine D. Van Raamsdonk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
J. William Harbour et al.
SCIENCE (2010)
The PI3K/Akt and mTOR/P70S6K Signaling Pathways in Human Uveal Melanoma Cells: Interaction with B-Raf/ERK
Narjes Babchia et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2010)
Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma
J. Bauer et al.
BRITISH JOURNAL OF CANCER (2009)
Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model
Cedo M. Bagi et al.
CANCER BIOLOGY & THERAPY (2009)
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Catherine D. Van Raamsdonk et al.
NATURE (2009)
Targeted therapy for uveal melanoma
Pierre L. Triozzi et al.
CANCER TREATMENT REVIEWS (2008)
Oncogenic Mutations in GNAQ Occur Early in Uveal Melanoma
Michael D. Onken et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2008)
Incidence of uveal melanoma in Europe
Gianni Virgili et al.
OPHTHALMOLOGY (2007)
Mitogenic signaling pathways induced by G protein-coupled receptors
Enrique Rozengurt
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma
Jyotsnabaran Halder et al.
CANCER RESEARCH (2007)
Clinical and cytogenetic analyses in uveal melanoma
Emine Kilic et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2006)
The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts
JR Graff et al.
CANCER RESEARCH (2005)
Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS
W Zuidervaart et al.
BRITISH JOURNAL OF CANCER (2005)
Effects of G-protein mutations on skin color
CD Van Raamsdonk et al.
NATURE GENETICS (2004)
Screening for metastasis from choroidal melanoma: The Collaborative Ocular Melanoma Study Group report 23
M Diener-West et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Dermal dendritic melanocytic proliferations: an update
A Zembowicz et al.
HISTOPATHOLOGY (2004)
Integration of DAG signaling systems mediated by PKC-dependent phosphorylation of RasGRP3
C Teixeira et al.
BLOOD (2003)
YM-254890, a novel platelet aggregation inhibitor produced by Chromobacterium sp QS3666
M Taniguchi et al.
JOURNAL OF ANTIBIOTICS (2003)
Monosomy 3 in uveal melanoma: Correlation with clinical and histologic predictors of survival
AGM Scholes et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2003)
Very long-term prognosis of patients with malignant uveal melanoma
E Kujala et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2003)
Share Paper
